Isis Pharmaceuticals Hits New 1-Year High at $51.85 (ISIS)
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) hit a new 52-week high on Thursday , American Banking and Market News reports. The stock traded as high as $51.85 and last traded at $51.76, with a volume of 711,890 shares trading hands. The stock had previously closed at $50.86.
A number of research firms have recently commented on ISIS. Analysts at Deutsche Bank initiated coverage on shares of Isis Pharmaceuticals in a research note on Wednesday, January 22nd. They set a “buy” rating and a $60.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Isis Pharmaceuticals in a research note on Tuesday, January 21st. They now have a $49.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Isis Pharmaceuticals from an “underweight” rating to a “neutral” rating in a research note on Tuesday, November 26th. They now have a $38.00 price target on the stock, up previously from $25.00. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. Isis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $39.50.
In other Isis Pharmaceuticals news, COO B Lynne Parshall sold 89,510 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $49.49, for a total value of $4,429,849.90. Following the completion of the transaction, the chief operating officer now directly owns 4,022 shares of the company’s stock, valued at approximately $199,049. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.